Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.

Genes, chromosomes & cancer - 1 Dec 1997

Tseng S L, Yu I C, Yue C T, Chang S F, Chang T M, Wu C W, Shen C Y

Abstract excerpt

Cells with abnormal TP53 lose cell cycle checkpoints, resulting in genomic instability and neoplastic transformation. However, the evidence linking the tumor-specific targets of genomic alteration to an abnormal TP53 is limited. The present study tested the hypothesis that TP53 abnormalities are correlated with an increased frequency of deletion of breast cancer susceptibility loci (17q and 13q) in breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Deletion

Share to Genes, p53

Share to Immunohistochemistry

Share to Microsatellite Repeats

Share to Mutation

Source

Identifiers

PMID: 9408754

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allelic loss at BRCA1, BRCA2, and adjacent loci in relation to TP53 abnormality in breast cancer.PMID 9408754Read ↗

Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.Semantic proximity Read ↗

Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas.Semantic proximity Read ↗

Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.Semantic proximity Read ↗

Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.Semantic proximity Read ↗

Deletion of 17p in cancers: Guilt by (p53) associationSemantic proximity Read ↗

Accumulation of genetic alterations and progression of primary breast cancer.Semantic proximity Read ↗

Genetic alterations in breast cancer.Semantic proximity Read ↗

Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis.Semantic proximity Read ↗

Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p.Semantic proximity Read ↗

Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors.Semantic proximity Read ↗

Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.Semantic proximity Read ↗

Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.